-
1 Comment
Avid Bioservices, Inc is currently in a long term uptrend where the price is trading 67.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.7.
Avid Bioservices, Inc's total revenue rose by 60.5% to $22M since the same quarter in the previous year.
Its net income has increased by 204.9% to $2M since the same quarter in the previous year.
Finally, its free cash flow grew by 191.6% to $2M since the same quarter in the previous year.
Based on the above factors, Avid Bioservices, Inc gets an overall score of 5/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US05368M1062 |
Sector | Healthcare |
Industry | Biotechnology |
Dividend Yield | None |
---|---|
Target Price | 12.5 |
Beta | 1.41 |
Market Cap | 799M |
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CDMO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025